Telix Pharmaceuticals delivered strong H1 2026 results that underscore the company’s ability to execute commercially while advancing a late-stage pipeline. Group revenue reached US$477 million, representing 22% year-over-year growth and tracking toward the upper end of full-year guidance of US$950 million to US$970 million. The performance is particularly noteworthy given that it was achieved alongside increased R&D spending of US$124 million directed at advancing multiple late-stage programs, suggesting the company is balancing near-term profitability with long-term value creation.
The financial metrics reveal improving unit economics. Gross margin expanded to 55%, up 200 basis points year-over-year, with the Precision Medicine segment achieving 65% gross margin. More impressively, adjusted EBITDA surged 146% to US$52 million, though this includes a US$40 million non-refundable payment from the newly announced strategic collaboration with Regeneron. Even excluding this windfall, the underlying cash generation improvement reflects operational leverage as the company scales its commercial footprint while maintaining disciplined cost management.
The Precision Medicine segment remains the growth engine, with revenue up 27% year-over-year driven by volume expansion in Illuccix and Gozellix, Telix’s two-product strategy for prostate cancer imaging. Both products are gaining market share, with patient enrollment in the Phase 3 BiPASS study nearing completion and enrollment now finished for the Illuccix Japan registrational trial. These data sets could unlock additional approvals and market opportunities within the next 12 months.
Beyond Precision Medicine, multiple catalysts are queued for the second half of 2026. The company achieved a September 11 PDUFA goal date for Pixclara, its brain cancer imaging agent, while the European MAA for Pixlumi has been validated. The Illuccix new drug application is under review by China’s NMPA. Each approval would extend Telix’s addressable market and diversify its revenue streams. The Regeneron partnership also validates the company’s platform technology and brings significant capital and commercialization expertise to the table.
The balance sheet strengthened materially during the period. Telix refinanced its convertible bond structure by issuing US$600 million of new bonds due 2031, extending the maturity profile and providing flexibility. Cash on hand stands at US$252 million with positive operating cash flow of US$23 million generated during the half. This financial position enables the company to invest in manufacturing capacity and geographic expansion without distress. Investors should monitor near-term regulatory outcomes for Pixclara and the Chinese NMPA review alongside full-year revenue guidance execution. This announcement is price sensitive and has been classified as material by the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
